Mary-Elizabeth Patti MD, FACPInvestigator, Adult Endocrinologist, and Director, Hypoglycemia Clinic, Joslin Diabetes Center; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts
Dr. Patti is a physician-scientist, serving as Principal Investigator at Joslin Diabetes Center, Director of the Hypoglycemia Clinic, Co-Director of the Molecular Phenotyping Core, and Associate Professor of Medicine at Harvard Medical School. Dr. Patti’s NIH-funded lab focuses on identification of molecular/epigenetic mechanisms by which nutritional exposures during early life increase diabetes risk in subsequent generations. Translational studies are focused on mechanisms contributing to diabetes resolution and hypoglycemia after bariatric surgery. Dr. Patti received her MD from Jefferson Medical College magna cum laude, with internal medicine residency at University of Pittsburgh, and endocrinology fellowship at Harvard.
Dr. Patti gratefully acknowledges support from NIH R01 DK121995, R01 DK106193, U01 DK114156, P30 DK036836 (DRC, Joslin Diabetes Center) and the Chan Zuckerberg Foundation.
Dr. Patti has been a coinvestigator on an NIH R44 grant together with Xeris Pharmaceuticals. She has consulted for Eiger Pharmaceuticals, has received investigator-initiated grant support from Janssen Pharmaceuticals, Medimmune, Sanofi, Astra-Zeneca, Jenesis, and Nuclea, has been a site investigator for XOMA and Xeris, and acknowledges clinical trial research trial product support from Ethicon, Covidien, NovoNordisk, Nestle, and Dexcom within the past 5 years – all unrelated to the present study. Dr. Patti has submitted a patent application regarding plasma proteins contributing to hypoglycemia and pump therapies for hypoglycemia. No other relationships or activities occurred that could appear to have influenced the submitted work.
Recent Contributions to PracticeUpdate:
- Impact of Starting BMI and Degree of Weight Loss in Appetite-Regulating Hormone Changes During Diet-Induced Weight Loss
- Roux-en-Y Gastric Bypass Increases Glycemic Variability and Time in Hypoglycemia
- Effects of Acarbose, Sitagliptin, Verapamil, Liraglutide, and Pasireotide on Postprandial Hypoglycemia After RYGB
- Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass in Type 2 Diabetes
- The Primary Glucose-Lowering Effect of Metformin Resides in the Gut